NAXS : Nordic Capital och Five Arrows avyttrar The Binding Site, en global ledare inom specialty diagnostics, till Thermo Fisher Scientific
November 01, 2022 at 04:56 am
Share
Nordic Capital och Five Arrows avyttrar The Binding Site, en global ledare inom specialty diagnostics, till Thermo Fisher Scientific
1 november 2022
Nordic Capital and Five Arrows have entered into a definitive agreement to sell The Binding Site, a global leader in specialty diagnostics, to Thermo Fisher Scientific (NYSE:TMO), the world leader in serving science. The transaction is valued at GBP 2.25 billion. Since the acquisition of The Binding Site in 2011, the business has made an impressive transformation from a founder-led research-based organisation to a leader in delivering innovative medical solutions that improve the detection, diagnosis and management of blood cancers and immune system disorders.
The transformation has been achieved by significant investments into its technology, growth and with a dedicated focus on R&D to support research and drive improved clinical outcomes. Since 2011, The Binding Site has grown fivefold with revenues amounted to approximately GBP 200 mn in 2022 and more than 40 million tests sold on a global scale. The Binding Site's Freelite® offering is widely recommended for Multiple Myeloma diagnosis and monitoring across multiple stages of the disease by many major clinical diagnosis and treatment guideline publications. By joining Thermo Fisher Scientific, the world leader in serving science, The Binding Site will be even better positioned to accelerate scientific discovery and expand its product offering.
Dela denna artikel
Attachments
Original Link
Original Document
Permalink
Disclaimer
NAXS AB published this content on 01 November 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 01 November 2022 08:55:08 UTC.
NAXS AB (publ) is a Sweden-based investment company. It primarily invests in a private equity funds in Northern Europe, as well as directly invests or makes co-investments alongside private equity or other alternative assets funds. The Company has focus on such sectors as healthcare, consumer goods and services, industry, information technology and telecommunication, building and construction, media, financial and business services. Its portfolio consists of nine funds, namely Apax Europe VII, FSN Capital III, Herkules Private Equity Fund III, Intera Fund I, Intera Fund II, Mimir Invest AB, Nordic Capital Fund VII, Valedo Partners Fund I, Valedo Partners Fund II. The Company is majority-owned by Tompkins Square Park S.a.r.l.